Thanks for sharing your inspuring story.
The two RAC melanoma preclinicals were very promising.
The immediate "problem" is that in Australia (and I guess in other high income countries) doxorubicin isn't used for melanoma. So melanoma patients can't be in RAC's upcoming trial.
It looks as if a clinical trial of bisantrene for melanoma will have to wait after the lower-hanging fruit has been picked.
BTW, RAC may have changed ownership by then.
Industry news, page-2334
-
- There are more pages in this discussion • 72 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.77%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.59 | $1.53 | $83.43K | 53.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20575 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |